Quick Answer
Insight Molecular Diagnostics Inc. reported Stockholders Equity of -$31.46 million for fiscal year 2025.
Insight Molecular Diagnostics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$31.46M | -156.3% |
| 2024 | -$12.27M | -160.0% |
| 2023 | $20.47M | -40.3% |
| 2022 | $34.29M | -47.4% |
| 2021 | $65.22M | +94.8% |
| 2020 | $33.48M | +8.6% |
| 2019 | $30.84M | +800.9% |
| 2018 | $3.42M | -22.3% |
| 2017 | $4.40M | -55.4% |
| 2016 | $9.86M | -5.3% |
| 2015 | $10.42M | +1069.9% |
| 2014 | -$1.07M | -129.7% |
| 2013 | $3.62M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$9.20M | -194.7% | -937.5% |
| June 30, 2025 | $1.10M | -95.2% | -89.3% |
| March 31, 2025 | $10.22M | -11.8% | +183.2% |
| December 31, 2024 | -$12.27M | -160.0% | -226.4% |
| September 30, 2024 | $9.71M | -73.1% | -57.2% |
| June 30, 2024 | $22.70M | -47.9% | +95.9% |
| March 31, 2024 | $11.59M | -69.5% | -43.4% |
| December 31, 2023 | $20.47M | -40.3% | -43.4% |
- Insight Molecular Diagnostics Inc. showed a decrease of -156.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2025 period, Insight Molecular Diagnostics Inc.’s stockholders equity has declined by 970.4% (from $3.62 million to -$31.46 million).
- The most recent figure is from Insight Molecular Diagnostics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: